Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Malignant Lymphoma

  Free Subscription


25.08.2025

1 Am J Clin Pathol
1 Am J Hematol
4 Blood
3 BMC Cancer
1 Bone Marrow Transplant
2 Br J Dermatol
2 Br J Haematol
1 Haematologica
1 J Am Acad Dermatol
3 Leuk Lymphoma
1 N Engl J Med
2 PLoS One


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Clin Pathol

  1. TAKEDA K, Tang H, Kumar D, Adeniran AJ, et al
    Clinicopathologic characteristics of lymphoproliferative disorders involving the kidney.
    Am J Clin Pathol. 2025;164:192-199.
    PubMed         Abstract available


    Am J Hematol

  2. OTHMAN T, Baird JH, Wang Y, Pak S, et al
    Outpatient Brexucabtagene Autoleucel in B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma.
    Am J Hematol. 2025 Aug 20. doi: 10.1002/ajh.70038.
    PubMed        


    Blood

  3. SCHERER F
    Cracking the POD24 code in follicular lymphoma.
    Blood. 2025;146:899-900.
    PubMed        


  4. Allo-HCT in Hodgkin lymphoma after CPI.
    Blood. 2025;146:1030.
    PubMed        

  5. XU P, Zhu Y, Shi ZY, Wang L, et al
    A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma.
    Blood. 2025 Aug 19:blood.2025028649. doi: 10.1182/blood.2025028649.
    PubMed         Abstract available

  6. REJESKI K, Sanz J, Fei T, Nair MS, et al
    T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy.
    Blood. 2025;146:834-846.
    PubMed         Abstract available


    BMC Cancer

  7. HEROLD S, Schmidt C, Visco C, Tilch MK, et al
    The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell ly
    BMC Cancer. 2025;25:1370.
    PubMed         Abstract available

  8. AL-MANSOUR M, Alghanmi HA, Shareef DE, Alshamat ES, et al
    Treatment patterns and survival outcomes of peripheral T-Cell lymphoma in Saudi Arabia: a 12-Year retrospective analysis.
    BMC Cancer. 2025;25:1361.
    PubMed         Abstract available

  9. GAO L, Wang L, Xue C, Cen X, et al
    Peripheral EBV antigen-specific T cell is dysfunctional in Epstein-Barr virus positive diffuse large B-cell lymphoma.
    BMC Cancer. 2025;25:1318.
    PubMed         Abstract available


    Bone Marrow Transplant

  10. DONG Y, Yang T, Zhao M, Song F, et al
    Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2025 Aug 20. doi: 10.1038/s41409-025-02691.
    PubMed         Abstract available


    Br J Dermatol

  11. DOELEMAN T, Beljaards ESM, Ottevanger R, Jansen P, et al
    Added value of pathology consultations in cutaneous lymphomas: a 2-year review from the Dutch national referral and expertise centre.
    Br J Dermatol. 2025 May 14:ljaf184. doi: 10.1093.
    PubMed         Abstract available

  12. HODAK E, Amitay-Laish I, Bagot M, Battistella M, et al
    ISCL/EORTC-CLTG/USCLC recommendations for the diagnosis, staging and treatment of early-stage paediatric mycosis fungoides: a modified Delphi consensus. Part one: diagnosis and staging.
    Br J Dermatol. 2025;193:405-414.
    PubMed         Abstract available


    Br J Haematol

  13. YU F, Yu X, Hu X, Jiang E, et al
    Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2025 Aug 26. doi: 10.1111/bjh.70102.
    PubMed         Abstract available

  14. KOCA O, Eskazan AE
    Refining the risk stratification in advanced-stage classical Hodgkin lymphoma: A critical analysis of clinical prediction models.
    Br J Haematol. 2025 Aug 22. doi: 10.1111/bjh.70115.
    PubMed         Abstract available


    Haematologica

  15. MOLLA R, Bantilan K, Berman E, Caron P, et al
    Two decades of single-institution data reveal rare long-term survivors of relapsed/refractory Burkitt lymphoma.
    Haematologica. 2025 Aug 7. doi: 10.3324/haematol.2024.287165.
    PubMed         Abstract available


    J Am Acad Dermatol

  16. PANG Y, Thomas ZO, Ayanruoh LD, Enriquez GH, et al
    Skin microbiota differs between Black and White patients with cutaneous T-cell lymphoma.
    J Am Acad Dermatol. 2025 Aug 22:S0190-9622(25)02675.
    PubMed        


    Leuk Lymphoma

  17. CHUMNUMSIRIWATH P, Vittayawacharin P, Pinter-Brown L, Brem EA, et al
    Lite-BEAM expands autologous stem cell transplantation access for older or unfit patients with lymphoma.
    Leuk Lymphoma. 2025 Aug 21:1-5. doi: 10.1080/10428194.2025.2547985.
    PubMed        

  18. ISKIERKA-JAZDZEWSKA E, Kim WS, Cho SG, Kim TM, et al
    Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy.
    Leuk Lymphoma. 2025 Aug 20:1-12. doi: 10.1080/10428194.2025.2535694.
    PubMed         Abstract available

  19. MATARASSO GREENFELD S, Dmitrienko S, Shrier I, Deschenes JL, et al
    Understanding the clinical approach to "pathologically ambiguous follicular lymphoma" through a Real-World cohort.
    Leuk Lymphoma. 2025 Aug 18:1-4. doi: 10.1080/10428194.2025.2542943.
    PubMed        


    N Engl J Med

  20. ALEMAN A, Van Oekelen O, Melnekoff DT, Grossman L, et al
    Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy.
    N Engl J Med. 2025;393:823-825.
    PubMed        


    PLoS One

  21. XU L, Tu G, Cai Z, Lan T, et al
    Predicting in-hospital mortality in ICU patients with lymphoma using machine learning models.
    PLoS One. 2025;20:e0330197.
    PubMed         Abstract available

  22. ERDOGAN MS
    On nonparametric estimating ROC curve based on non-uniform rational B-spline.
    PLoS One. 2025;20:e0330175.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.